- Home
- QUMS vs UNCY Comparison
QUMS vs UNCY Comparison
Compare QUMS & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QUMS | UNCY |
|---|---|---|
| Founded | 2024 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.7M | 121.9M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QUMS | UNCY |
|---|---|---|
| Price | $9.98 | $6.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 55.2K | ★ 441.0K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.92 | $3.71 |
| 52 Week High | $10.23 | $11.00 |
Technical Indicators
Market Signals| Indicator | QUMS | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 63.56 |
| Support Level | N/A | $6.06 |
| Resistance Level | N/A | $6.70 |
| Average True Range (ATR) | 0.00 | 0.43 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 0.00 | 75.34 |
Price Performance
Historical ComparisonAbout QUMS Quantumsphere Acquisition Corp. Ordinary Shares
Quantumsphere Acquisition Corp is a newly organized blank check company.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.